ClinicalTrials.gg
RecruitingNCT06892951CaspoNEBUpdated Oct 9, 2026

CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

A Phase 1/2 interventional study of Caspofungin Acetate 50 MG and Physiologic saline in Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection and Pneumocystis Infections, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University Hospital, Tours · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pneumonia, Pneumocystis with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Pneumonia, Pneumocystis · France.

Started
2025
with 1 other
Phase 1/2
Only one
of the 15
Registered
12th of 15
by date

Among the 15 studies in Pneumonia, Pneumocystis with a site in France, this one is one of 2 that started in 2025, is the only one in phase 1/2, and was the 12th registered.

Pneumonia, Pneumocystis

108 studies on the registry are indexed under Pneumonia, Pneumocystis; 16 are open to participants now.

Browse Pneumonia, Pneumocystis studies →

Open to participants now

3 of the 15 studies in Pneumonia, Pneumocystis with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 9 Pneumonia, Pneumocystis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pneumonia, Pneumocystis with a site in France, or all of them as a file.
02

Study summary

To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.

Read the detailed description

Pneumocystis jirovecii is an airborne-transmissible fungus which can induce pneumonia with severely impaired lung function, especially in immunocompromised patients. At least 1,000 new cases of Pneumocystis pneumonia occur each year in France with approximately 50% of cases suffering from hypoxemia. Around 15% HIV+ and 50% HIV- subjects require mechanical ventilation, and mean duration of hospitalization is about 30 days. Average mortality rate is ≈20% at 3 months, higher for critically ill patients (30%-60%).

To date, cotrimoxazole represents the gold standard anti-Pneumocystis treatment commonly associated with systemic corticosteroids in case of moderate-to-severe infection. However, treatment is long (several weeks) to achieve clearance of the fungus, which might favor lung sequelae like persistent inflammation or post-infectious fibrosis. Furthermore, therapeutic failures have been reported as high as 9-44% of patients. Five other drugs have been commonly used as curative alternatives to cotrimoxazole against P. jirovecii: pentamidine, primaquine + clindamycin, dapsone and atovaquone. Some are responsible for serious side effects, while others are complex to administer or less efficient. All exhibit clinically important drug-drug interactions. Therefore, in such a context, it is important to test new drugs and/or alternative delivery routes for existing therapies.

Echinocandin drugs, including caspofungin, are usually administered daily to treat invasive candidiasis and aspergillosis. They target the fungal cell wall, thus inhibiting the β-(1,3)-D glucan synthase enzyme. Intravenous (IV) echinocandins are generally well tolerated and are not responsibles for major drug-drug interactions. IV caspofungin was also proven effective in animal models of Pneumocystis infection and significantly improve the overall survival. Two human studies showed that in-hospital and 3-month mortality rates were similar between patients receiving daily IV echinocandin and those receiving co-trimoxazole alone. Several case reports also showed 47 successful outcomes with IV caspofungin, alone or in combination with standard treatment. A recent study reported better response and lower in-hospital mortality in patients receiving the combination of cotrimoxazole + IV caspofungin with no severe adverse events. Therefore, IV echinocandins are now recommended in the European therapeutic guidelines for non-HIV patients as a salvage therapy (CII-grade) in association with co-trimoxazole.

However, high molecular weight and elevated protein binding hamper optimal diffusion of IV caspofungin towards the lung alveoli (\<5% plasma concentration), where P. jirovecii thrives. Administration through an aerosol directly delivered into the lung may circumvent this limitation. Technical feasibility of echinocandin nebulization was demonstrated in vitro with several commercial nebulizers that provided aerosol particles with adequat size and pH to ensure lung tolerance. In vivo, nebulized caspofungin, at a dosage equivalent to the usual IV dosage, showed an excellent safety profile in rats. It also reduced the fungal burden by -99% and induced elevated and prolonged concentrations of the drug in the lungs (almost 50% of the total amounts of caspofungin initially deposited into the lungs of infected rats were still detectable at 48 hours) - largely above the usual minimal inhibitory concentrations of fungal pathogens -, while caspofungin detection was almost null in other organs and blood.

Therefore, we hypothesize herein the therapeutic interest of caspofungin aerosols in adjunction with conventional antifungal therapy, as first-line curative treatment, to enhance the clinical recovery and to reduce the morbidity due to Pneumocystis pneumonia. As no clinical trials have been worldwide initiated, human efficacy and safety data of nebulized caspofungin are still lacking and will be first investigated in this study in patients. Thus organized in two successive parts, this phase I/II clinical trial represents a mandatory prelude for this original administration modality of caspofungin.

03

Conditions studied

  • Pneumocystis Pneumonia
  • Pneumocystis Jirovecii Infection
  • Pneumocystis Infections

Keywords

  • ventilation
  • Pneumocystis
  • caspofungin
  • echinocandin
  • aerosol
  • inhalation
  • nebulization
  • interstitial pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Male and female ≥18 years
  • Medical management of Pneumocystis pneumonia based on :

    • Microbiological diagnosis of Pneumocystis pneumonia
    • Respiratory support (oxygen therapy or ventilatory assistance)
    • Systemic co-trimoxazole therapy or systemic anti-Pneumocystis salvage therapy (switch to another anti-Pneumocystis drug is possible, but should be notified) (initiated within 48 hours or less before enrolment)
  • Person affiliated to a French social security system or equivalent
  • Written obtained from the participant or, if the patient is not able to give consent from representative (trusted person, family member) or if the delay in obtaining the consent is assumed not compatible with the enrollment requirements, a temporary approval can be obtained from the investigator. In all cases, the patient's written informed consent will have to be obtained as soon as possible.

Non-inclusion criteria:

  • Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship). Pregnancy test to be performed in all women from 15 to 45 years old who have not had an ovariectomy.
  • Other indication(s) for systemic administration of an echinocandin drug
  • Known allergy to echinocandin drugs
  • Absolute to aerosol therapy
  • Concomitant co-infection at time of diagnosis (except infection)
  • Severe liver impairment (i.e. documented severe liver cirrhosis (Child C), or Factor-V protein \< 50% and/or for prothrombin time of blood coagulation > 1.5)
  • history of toxic epidermal necrosis (TEN) and Steven-Johnson syndrome (SJS)
  • Participation in other pharmacological study that focuses on echinocandins and/or anti-infectious aerosol therapy or other anti-pneumocystis treatment
  • Participation in a trial with an product known to have pulmonary toxicity or of which the safety is not known
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Part 2 - randomized study (group 1)

    Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second line anti-Pneumocystis salvage therapy) + aerosols of echinocandin (50 mg caspofungin) during one to seven days (according to the regimen retained from the results of part 1 from day-1 to d-7) using vibrating mesh nebulization device

    Drug: Caspofungin Acetate 50 MG

  • Placebo comparator
    Part 2 - randomized study (group 2)

    Control group: (in part 2 only) Conventional systemic antifungal treatment (systemic co-trimoxazole or systemic second-line anti-Pneumocystis salvage therapy) + aerosols of placebo (0.9% saline in a volume equivalent to the experimental group) during one to seven days (according to the regimen retained from part 1 results) using vibrating mesh nebulization device

    Drug: Physiologic saline

  • Experimental
    Part 1 - open study

    open-label non-randomized group, with ascending scheme regarding the dose and rhythm of administration over one week, depending on the tolerance, and closely monitored in ICU to ensure that caspofungin is well tolerated via the inhaled route, and to provide data supporting the proposed administration scheme for part 2. * the first two patients (included one by one) will receive two aerosols (5 mg) during the first week, four days apart on d-1 and d-5 (level 1); * the third and fourth will receive two aerosols (15 mg) during the first week, four days apart on d-1 and d-5 (level 2); * the fifth and sixth will receive two aerosols (50 mg) during the first week, four days apart on d-1 and d-5 (level 3); * the seventh and eighth patients will receive four aerosols (50 mg) two days apart during one week, at d-1, then d-3, d-5 and d-7 (level 4); * the last two patients will have daily aerosols during the first week, from d-1 to d-7 (level 5)

    Drug: Caspofungin Acetate 50 MG

Interventions

  • DrugCaspofunginStudies of CaspofunginCaspofungin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The experimental treatment will be administered once daily for up to seven days, through the nebulization route by the means of a disposable vibrating mesh Aeroneb solo® nebulizer with the valved mask (Galway, Ireland). Before generating aerosol, resuspension of the caspofungin powder will be carried out in the same manner than for the IV route, into 10.5 mL saline serum. Preparation of the experimental drug (re-suspension) will be unblindly carried out in a distinct medical office by a nurse neither involved in the healthcare of the included patients, nor in the other parts of the study, data recording or outcome assessment. Once reconstituted, the suspension is expected to be limpid, with neither odour nor foam. Thereafter, its administration will be blindly completed by the clinical staff in charge of the enrolled patient.

  • DrugPhysiologic saline

    Procedures will be exactly the same than those described above for the experimental group, but caspofungin will be replaced during the seven days of intervention by 10mL of 0.9% saline nebulized in the control group for a 15 minute-long process of nebulization (from d-1 to d-7).

06

What researchers measure

Primary outcomes

  1. Part 1: safety of inhaled caspofungin

    * frequency of adverse events * severity of adverse events

    Time frame: D-7 (day-7)

  2. Part 2: proportion of patients alive and with a favorable clinical course* at the seventh day (day-7) after the first administration.

    Composite outcome defined by at least one of the two following items persisting ≥24 hours in alive patients: * Relative reduction (de-escalation or withdrawal) of respiratory assistance due to clinical improvement (depending on the initial support): * extubation, or * weaning of non-invasive ventilatory support, or * weaning of nasal high-flow or low-flow oxygen therapy; (NB: all participating centers will implement uniform protocols for ventilatory assistance weaning) * Occurrence of a +50% increase in oxygenation (PaO2 / FiO2 ratio vs. the worst value observed after inclusion).

    Time frame: D7 (day-7)

Secondary outcomes

  1. Individual components of the composite primary outcome at day-7 (d-7)

    * All-cause mortality and Pneumocystis pneumonia-related mortality * Improvement of respiratory function: * Proportion of patients alive and with relative reduction (de-escalation or withdrawal) of respiratory assistance (in percentage) * Proportion of patients alive and with a +50% increase in oxygenation (PaO2 / FiO2 ratio vs. the worst value observed after inclusion) (in percentage)

    Time frame: D7 (day-7)

  2. Safety of nebulized caspofungin in patients with Pneumocystis pneumonia through

    * Occurrence of serious and non-serious pulmonary adverse events and adverse effects at day-1 (d-1), d-2, d-3, d-4, d-5, d-6, and d-7 (with active monitoring of the nebulization procedure), and serious pulmonary adverse events and adverse effects at hospital discharge, d-28 and d-90 * Occurrence of other serious adverse events and adverse effects at day-1 (d-1), d-2, d-3, d-4, d-5, d-6, d-7, hospital discharge, d-28 and d-90 * Liver and kidney markers at day 1 (d-1), d-3, d-7, d-28 and d-90 * transaminases (in international units/liter) * glutamate transferase (in international units/liter) * alkaline phosphatase (in international units/liter) * serum creatinine (in micromol/liter) * urea (in millimol/liter) * Blood counts (same dates) * complete blood count (in giga/liter) * platelets (in giga/liter) * Serum electrolytes (same dates) * sodium (in mmol/liter) * potassium (in mmol/liter) * chloride (in mmol/liter) * bicarbonates (in mmol/liter)

    Time frame: day-1 (d-1), d-2, d-3, d-4, d-5, d-6, and d-7

  3. Pharmacokinetics of nebulized caspofungin

    in blood at 0, 2, 4, 6, 12, 24 hours, plus residual concentration at day-3 (d-3) and d-7 for the five first included patients receiving caspofungin, and in tracheo-bronchial aspirates at 4, 6, 24 h, at day-3 (d-3) and d-7 (or just before extubation if still alive at time of extubation) for the five first included patients receiving caspofungin and who are intubated. Caspofungin concentration measurements (in milligram/liter) will be centrally carried out at Tours university hospital at the end of the study only for patients who received nebulized caspofungin (intervention group), once the blind process will be lifted).

    Time frame: 0, 2, 4, 6, 12, 24 hours, plus residual concentration at day (d-3) and d-7

  4. Mortality

    * All-cause at hospital discharge, day-28 (d-28) and d-90 * Pneumocystis pneumonia-related at hospital discharge, day-28 (d-28) and d-90

    Time frame: day-28 (d-28) and d-90

  5. Morbidity

    * Number of days alive without any ventilatory / oxygen support * Duration to clinical stability (from inclusion to hospital discharge: * maximum daily temperature ≤ 37.8 °C * maximum daily heart pace ≤ 100 bpm * maximum daily respiratory pace ≤ 24 cpm * minimum daily systolic blood pressure ≥ 90 mmHg * arterial oxygenation saturation ≥ 90% or PaO2 ≥ 60 mmHg while breathing room air, or PaO2/FiO2 ratio ≥ 285 mmHg, without an increase in the intensity of the ventilatory support * normal mental status * Duration of invasive ventilatory support * Duration of invasive and non-invasive ventilatory support * Duration to clinical healing : * clinical stability (cf. above) * 24h weaning of mechanical respiratory support due to patient's clinical improvement * Duration of hospital stay (in days) * Duration of ICU stay (in days) * Change in the sepsis-related organ failure assessments (SOFA) score * Requirement of a second-line (salvage) anti-Pneumocystis curative therapy (yes or no)

    Time frame: day-1 (d-1), d-7 and d-21

  6. Pulmonary and systemic markers of lung infection (to assess the fungal clearance)

    * Evolution of hypoxemia: • alveolar-to-arterial oxygen gradient, ratio of arterial partial pressure in oxygen and pulsed oxymetry to fraction of inspired oxygen (in millimeter Hg) * LDH enzyme in blood (in international units/liter) * BDG fungal antigen in blood (in pigogram / milliliter) * RT-qPCR for P jirovecii nucleic acids in blood and in tracheal aspirates (in number of amplification cycles) * Impact on the micro-organism diversity in respiratory airways and infections * monitoring the expression of specific genes for distinguishing the relative representativeness between P. jirovecii asci and trophic forms from trachea-bronchial aspirates * identification and counting of fungal colonies from trachea-bronchial aspirates (in number of colony-forming units (CFU)) * identification and counting of bacterial colonies from trachea-bronchial aspirates (in CFU) * Genotyping of P. jirovecii strains based on microsatellites markers and sequencing of DHPS/DHFR genes in respiratory fluids

    Time frame: day-1 (d-1), d-3, d-7, d-28 and d-90

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Limper AH. Alveolar macrophage and glycoprotein responses to Pneumocystis carinii. Semin Respir Infect. 1998 Dec;13(4):339-47. PubMed 9872631 ↗
  • McKinnell JA, Cannella AP, Kunz DF, Hook EW 3rd, Moser SA, Miller LG, Baddley JW, Pappas PG. Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis. 2012 Oct;14(5):510-8. doi: 10.1111/j.1399-3062.2012.00739.x. Epub 2012 May 1. PubMed 22548840 ↗
  • Lobo ML, Esteves F, de Sousa B, Cardoso F, Cushion MT, Antunes F, Matos O. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. PLoS One. 2013 Aug 5;8(8):e70619. doi: 10.1371/journal.pone.0070619. Print 2013. PubMed 23940606 ↗
  • Wong-Beringer A, Lambros MP, Beringer PM, Johnson DL. Suitability of caspofungin for aerosol delivery: physicochemical profiling and nebulizer choice. Chest. 2005 Nov;128(5):3711-6. doi: 10.1378/chest.128.5.3711. PubMed 16304338 ↗
  • Ehrmann S, Mercier E, Vecellio L, Ternant D, Paintaud G, Dequin PF. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med. 2008 Apr;34(4):755-62. doi: 10.1007/s00134-007-0935-1. Epub 2007 Nov 29. PubMed 18046534 ↗
  • Beitler JR, Sarge T, Banner-Goodspeed VM, Gong MN, Cook D, Novack V, Loring SH, Talmor D; EPVent-2 Study Group. Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-Fio2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2019 Mar 5;321(9):846-857. doi: 10.1001/jama.2019.0555. PubMed 30776290 ↗
  • Desoubeaux G, Lemaignen A, Ehrmann S. Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: A therapeutic innovation likely relevant to investigate in a near future.... Int J Infect Dis. 2020 Jun;95:464-467. doi: 10.1016/j.ijid.2020.03.029. Epub 2020 Mar 16. No abstract available. PubMed 32194238 ↗
  • Le Gal S, Toubas D, Totet A, Dalle F, Abou Bacar A, Le Meur Y, Nevez G; Anofel Association. Pneumocystis Infection Outbreaks in Organ Transplantation Units in France: A Nation-Wide Survey. Clin Infect Dis. 2020 May 6;70(10):2216-2220. doi: 10.1093/cid/ciz901. PubMed 31633150 ↗
  • Desoubeaux G, Dominique M, Morio F, Thepault RA, Franck-Martel C, Tellier AC, Ferrandiere M, Hennequin C, Bernard L, Salame E, Bailly E, Chandenier J. Epidemiological Outbreaks of Pneumocystis jirovecii Pneumonia Are Not Limited to Kidney Transplant Recipients: Genotyping Confirms Common Source of Transmission in a Liver Transplantation Unit. J Clin Microbiol. 2016 May;54(5):1314-20. doi: 10.1128/JCM.00133-16. Epub 2016 Mar 2. PubMed 26935726 ↗
  • Alanio A, Desoubeaux G, Sarfati C, Hamane S, Bergeron A, Azoulay E, Molina JM, Derouin F, Menotti J. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect. 2011 Oct;17(10):1531-7. doi: 10.1111/j.1469-0691.2010.03400.x. Epub 2011 Apr 12. PubMed 20946413 ↗
  • Nevez G, Le Gal S. Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01296-19. doi: 10.1128/AAC.01296-19. Print 2019 Oct. No abstract available. PubMed 31548210 ↗
  • Peghin M, Fishman JA, Grossi PA. Pneumocystis jiroveci : still troublesome to diagnose and treat. Curr Opin Infect Dis. 2025 Dec 1;38(6):522-529. doi: 10.1097/QCO.0000000000001155. Epub 2025 Oct 17. PubMed 41151592 ↗

Individual participant data

Plan to share: Yes — All research data can be requested

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: At the end of the study (2028)

Access criteria: Upon request

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2025 → Dec 2025 and primary completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Mar 25, 2025
StartActual
Dec 2, 2025was Jun 2025
Primary completionEst.
Dec 2026was Jun 2026
CompletionEst.
Dec 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
2 sites added. CHU Tours is now Not yet recruiting
Show 2 added (2 France)
  • CHU Orléans · Orléans, France
  • CHRU Tours · Tours, France
Oct 9, 2026
Start date
Jun 2025→Dec 2, 2025 (actual)
Oct 9, 2026
Primary completion
Jun 2026→Dec 2026
Oct 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41151592 ↗
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41151592 ↗
    2 sites added. CHU Tours is now Not yet recruiting
    Show 2 added (2 France)
    • CHU Orléans · Orléans, France
    • CHRU Tours · Tours, France
    Start date Jun 2025→Dec 2, 2025 (now actual)
    Primary completion Jun 2026→Dec 2026
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06892951
Responsible party
Sponsor
First posted
Mar 25, 2025
Start date
Dec 2, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Guillaume DESOUBEAUX, Prof
Contact
guillaume.desoubeaux@univ-tours.fr
+33(0)2 34 37 89 26
Stephan EHRMANN, Prof
Contact
stephanehrmann@gmail.com
+33(0)6 71 10 33 02
Guillaume DESOUBEAUX, Prof
study director · University Hospital of TOURS
Stephan EHRMANN, Prof
study director · University Hospital of TOURS
Adrien LEMAIGNEN, Dr
study director · University Hospital of TOURS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Caspofungin

Start the discussion